Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection

Journal of Hepatology

Volumn 59, Issue 1, 2013, Pages 38-44

  Oliviero, Barbara ^a   Mele, Dalila ^a   Degasperi, Elisabetta ^c   Aghemo, Alessio ^c   Cremonesi, Eleonora ^a   Rumi, Maria Grazia ^c   Tinelli, Carmine ^a   Varchetta, Stefania ^a   Mantovani, Stefania ^a   Colombo, Massimo ^c   Mondelli, Mario U ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiviral therapy; Hepatitis C virus; Interferon alpha; Natural killer cells

Indexed keywords

CD16 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL THERAPY; ARTICLE; CELL KINETICS; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRANULATION; FLOW CYTOMETRY; HEPATITIS C; HOMOZYGOSITY; HUMAN; HUMAN CELL; MOLECULE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; GPI-LINKED PROTEINS; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; INTERFERON-ALPHA; KILLER CELLS, NATURAL; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; POLYETHYLENE GLYCOLS; PORE FORMING CYTOTOXIC PROTEINS; PROSPECTIVE STUDIES; RECEPTORS, IGG; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84879140583     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.03.003     Document Type: Article

References (35)

1. E. Vivier, D.H. Raulet, A. Moretta, M.A. Caligiuri, L. Zitvogel, and L.L. Lanier Innate or adaptive immunity? The example of natural killer cells Science 331 2011 44 49
2. B. Oliviero, S. Varchetta, E. Paudice, G. Michelone, M. Zaramella, and D. Mavilio Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections Gastroenterology 137 2009 1151 1160
3. P. Bonorino, M. Ramzan, X. Camous, T. Dufeu-Duchesne, M.A. Thelu, and N. Sturm Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C J Hepatol 51 2009 458 467
4. U.C. Meier, R.E. Owen, E. Taylor, A. Worth, N. Naoumov, and C. Willberg Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections J Virol 79 2005 12365 12374
5. L. Golden-Mason, L. Madrigal-Estebas, E. McGrath, M.J. Conroy, E.J. Ryan, and J.E. Hegarty Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure Gut 57 2008 1121 1128
6. C. Morishima, D.M. Paschal, C.C. Wang, C.S. Yoshihara, B.L. Wood, and A.E. Yeo Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing Hepatology 43 2006 573 580
7. V.D. Gonzalez, K. Falconer, N.K. Bjorkstrom, K.G. Blom, O. Weiland, and H.G. Ljunggren Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment J Immunol 183 2009 6612 6618
8. A. De Maria, M. Fogli, S. Mazza, M. Basso, A. Picciotto, and P. Costa Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients Eur J Immunol 37 2007 445 455
9. J. Nattermann, G. Feldmann, G. Ahlenstiel, B. Langhans, T. Sauerbruch, and U. Spengler Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C Gut 55 2006 869 877
10. G. Ahlenstiel, R.H. Titerence, C. Koh, B. Edlich, J.J. Feld, and Y. Rotman Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner Gastroenterology 138 2010 325 335
11. European Association for the Study of the L EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
12. J.J. Feld, and J.H. Hoofnagle Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 2005 967 972
13. G. Ahlenstiel, B. Edlich, L.J. Hogdal, Y. Rotman, M. Noureddin, and J.J. Feld Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C Gastroenterology 141 2011 1231 1239
14. B. Edlich, G. Ahlenstiel, A.Z. Azpiroz, J. Stoltzfus, M. Noureddin, and E. Serti Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients Hepatology 55 2012 39 48
15. S. Varchetta, D. Mele, S. Mantovani, B. Oliviero, E. Cremonesi, and S. Ludovisi Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection Hepatology 56 2012 841 849
16. B. Grzywacz, N. Kataria, and M.R. Verneris CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases Leukemia 21 2007 356 359
17. J. Jo, B. Bengsch, B. Seigel, S.J. Rau, J. Schmidt, and E. Bisse Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential J Hepatol 57 2012 9 16
18. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
19. T. Pembroke, I. Rees, K. Gallagher, E. Jones, P. Mizen, and T. Navruzov Rapid early innate control of hepatitis C virus during IFN-alpha treatment compromises adaptive CD4(+) T-cell immunity Eur J Immunol 42 2012 2383 2394
20. B. Rehermann, and C. Hepatitis Virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J Clin Invest 119 2009 1745 1754
21. K.A. Stegmann, N.K. Bjorkstrom, H. Veber, S. Ciesek, P. Riese, and J. Wiegand Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection Gastroenterology 138 2010 1885 1897
22. F. Bozzano, A. Picciotto, P. Costa, F. Marras, V. Fazio, and I. Hirsch Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment Eur J Immunol 41 2011 2905 2914
23. A. Chan, D.L. Hong, A. Atzberger, S. Kollnberger, A.D. Filer, and C.D. Buckley CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts J Immunol 179 2007 89 94
24. C. Romagnani, K. Juelke, M. Falco, B. Morandi, A. D'Agostino, and R. Costa CD56brightCD16- killer Ig-like receptor - NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation J Immunol 178 2007 4947 4955
25. M.A. Cooper, T.A. Fehniger, and M.A. Caligiuri The biology of human natural killer-cell subsets Trends Immunol 22 2001 633 640
26. J. Larkin, A. Bost, J.I. Glass, and S.L. Tan Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons J Interferon Cytokine Res 26 2006 854 865
27. J. Jo, U. Aichele, N. Kersting, R. Klein, P. Aichele, and E. Bisse Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model Gastroenterology 136 2009 1391 1401
28. O. Dessouki, Y. Kamiya, H. Nagahama, M. Tanaka, S. Suzu, and Y. Sasaki Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment Biochem Biophys Res Commun 393 2010 331 337
29. O. Penack, C. Gentilini, L. Fischer, A.M. Asemissen, C. Scheibenbogen, and E. Thiel CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets Leukemia 19 2005 835 840
30. M. Falco, R. Biassoni, C. Bottino, M. Vitale, S. Sivori, and R. Augugliaro Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells J Exp Med 190 1999 793 802
31. G. Nicoll, J. Ni, D. Liu, P. Klenerman, J. Munday, and S. Dubock Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes J Biol Chem 274 1999 34089 34095
32. L. Golden-Mason, K.M. Bambha, L. Cheng, C.D. Howell, M.W. Taylor, and P.J. Clark Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C Hepatology 54 2011 1559 1569
33. A. Balagopal, D.L. Thomas, and C.L. Thio IL28B and the control of hepatitis C virus infection Gastroenterology 139 2010 1865 1876
34. L. Golden-Mason, A.L. Cox, J.A. Randall, L. Cheng, and H.R. Rosen Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro Hepatology 52 2010 1581 1589
35. G. Alter, S. Jost, S. Rihn, L.L. Reyor, B.E. Nolan, and M. Ghebremichael Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance J Hepatol 55 2011 278 288 Matteo) Investimento per la Ricerca di Base, FIRB, Protocollo: RBAP10TPXK) Beatrice Vitiello